PO27 - The Homozygous Type II Antithrombin Deficient Pregnant Woman Monitored by Thrombin Generation Assay

Wednesday, June 26, 2024

13:00 – 14:00 ICT

Presenting Author(s)

Ivana Malikova, Mgr

Head of Laboratory
Charles University First Faculty of Medicine and General University Hospital in Prague
Prague, Hlavni mesto Praha, Czech Republic

Co-Author(s)

MH

Martina Husakova

Research worker
Charles University First Faculty of Medicine and General University Hospital in Prague
Prague, Hlavni mesto Praha, Czech Republic
JB

Jana Bilkova

Research worker
Charles University First Faculty of Medicine and General University Hospital in Prague
Prague, Hlavni mesto Praha, Czech Republic
RB

Radka Brzezkova

MD
Charles University First Faculty of Medicine and General University Hospital in Prague
Prague, Hlavni mesto Praha, Czech Republic
MM

Michaela Malíková

Research worker
Charles University First Faculty of Medicine and General University Hospital in Prague
Prague, Hlavni mesto Praha, Czech Republic

Background: We present the case study of a 28-year-old pregnant woman with antithrombin deficiency who was treated with low-molecular-weight heparin (LMWH).

Aims: To determine the utility of the thrombin generation assay (TGA) to monitor the effects of a prophylactic dose of low-molecular-weight heparin (LMWH) in a woman with homozygous antithrombin deficiency.

Methods: The thrombin generation was monitored via the Thrombin Generation Assay (TGA). We used Siemens diagnostic kits Berichrom® Antithrombin III (IIa) and INNOVANCE® Antithrombin to determine antithrombin activity. We used a chromogenic method for determination of factor Xa (FXa) inhibition.

Results: There were no thrombotic complications during the whole pregnancy of the observed woman. Antithrombin was administered before and after delivery, which was significantly reflected in the decrease in thrombin generation.

Conclusion(s): Consistent monitoring of thrombin generation with LMWH anticoagulant therapy administration during pregnancy together with antithrombin administration before and after delivery can improve the overall condition of pregnant women and the quality of their care.